Scope
The IAP–NNF quick-reference chapter addresses prevention, recognition and management of bronchopulmonary dysplasia in preterm infants. It emphasises reducing invasive support and excess oxygen, selective medication use, nutrition and detection of pulmonary hypertension. This summary excludes a contradictory dexamethasone dosing table.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Identify persistent respiratory needs and classify at the right time
- Suspect evolving bronchopulmonary dysplasia in a preterm infant below 32 weeks gestation who still needs oxygen, CPAP or ventilation beyond 14 days. Early recognition allows review of modifiable contributors. [1]
- Assess severity at 36 weeks postmenstrual age, or at discharge if earlier, according to respiratory support mode rather than oxygen concentration alone. The source uses a support-based classification. [1]
- If extubation remains unsuccessful after appropriate steroid treatment, caffeine and nutritional optimisation, investigate pulmonary hypertension, airway malacia or subglottic stenosis. [1]
Reduce invasive ventilation and excess oxygen exposure
- For infants below 32 weeks, the source recommends starting caffeine citrate within 24 hours, with a 20 mg/kg intravenous loading dose and maintenance of 5–10 mg/kg/day. Ensure the formulation is caffeine citrate when interpreting these doses. [1]
- Use early noninvasive support when feasible, avoid intubation where possible and extubate to CPAP or noninvasive positive-pressure ventilation promptly when stable. [1]
- For preterm infants receiving supplemental oxygen in the prevention pathway, target saturation of 90–95% and titrate inspired oxygen to the lowest effective level. Avoid unnecessary hyperoxia. [1]
- Do not routinely give inhaled nitric oxide to prevent bronchopulmonary dysplasia. [1]
Individualise support to lung mechanics and gas exchange
- For established disease, aim for the minimum respiratory support that maintains adequate gas exchange while avoiding both overdistension and atelectasis. [1]
- The stated established-disease oxygen target is 92–95%, with some centres accepting 90–95%. Keep this distinct from a mandate to pursue higher saturation with progressively more oxygen. [1]
- Recognise heterogeneous lung mechanics: some regions may collapse while others are hyperinflated. The source cautions against uniformly low end-expiratory pressure, and notes that airway malacia can require more pressure to keep airways open. [1]
Use medicines selectively and monitor complications
- Consider low-dose systemic dexamethasone for an infant who remains ventilator-dependent beyond 7–14 days despite caffeine and optimised ventilation. Do not use systemic dexamethasone before 7 days of life under this guidance. [1]
- During dexamethasone treatment, monitor glucose and blood pressure, watch for gastrointestinal bleeding or perforation, and avoid concurrent indomethacin or ibuprofen. Reassess respiratory response and consider stopping if no improvement is seen by day 3. [1]
- Do not use diuretics as routine maintenance for evolving disease. Reserve them selectively for acute pulmonary oedema exacerbations, with monitoring appropriate to the treatment. [1]
- Do not continue systemic furosemide beyond 5 days without monitoring electrolytes, calcium and renal ultrasound for nephrocalcinosis. [1]
- Avoid routine oral or systemic bronchodilators without documented reversible airway obstruction. Their availability in a drug table does not make them universal BPD treatment. [1]
Provide nutrition without excessive fluid volume
- For established BPD, the source suggests total fluids around 130–150 mL/kg/day, choosing the lower end with pulmonary oedema. Use daily weight and strict input–output records to guide fluid assessment. [1]
- Aim for energy intake of 130–150 kcal/kg/day and protein of 3.5–4.0 g/kg/day to support lung growth. Prefer enteral nutrition, including fortified expressed breast milk, rather than restricting protein to meet fluid limits. [1]
Screen and involve cardiology
- Perform echocardiographic screening at 36 weeks postmenstrual age in moderate-to-severe BPD. Consider an earlier study with labile hypoxaemia, recurrent cyanosis or oxygen needs disproportionate to chest radiograph findings. [1]
- For confirmed associated pulmonary hypertension, optimise the underlying lung disease, oxygenation, infection treatment and fluid management. Obtain cardiology input for every BPD-associated pulmonary hypertension case. [1]
Limitations and use
- The source DART table labels each listed amount as mg/kg/dose every 12 hours, but its stated cumulative dose is inconsistent with those entries. The detailed dexamethasone regimen is excluded and must not be inferred from this summary.
- Ventilator setting tables, vasodilator regimens and the graphical algorithm are not reproduced; they require full specialist context.
- This is source-grounded coverage of selected clear recommendations, not independent validation of every drug, dose, classification label or evidence claim in the quick-reference chapter.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Bronchopulmonary Dysplasia in Neonates
Selected recommendation material consulted
Publication details
- Issuing organisation
- IAP / NNF
- Resource type
- Quick-reference guideline · House clinical summary
- Source setting
- India
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.